Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
- PMID: 20203680
- DOI: 10.1038/nrgastro.2010.7
Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
Abstract
Background: A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform skin rash. The rash was not responsive to topical or oral corticosteroids and worsened after infliximab infusions and after subsequent administration of a second anti-TNF drug, adalimumab.
Investigations: Full medical history and physical examination, including assessment of the morphology of rash and the temporal correlation with administration of anti-TNF agents.
Diagnosis: Anti-TNF-agent induced psoriasiform skin rash.
Management: Discontinuation of anti-TNF therapy. The patient opted to have his gastrointestinal symptoms treated with oral mesalazine and metronidazole.
Similar articles
-
The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.J Crohns Colitis. 2014 Jun;8(6):480-8. doi: 10.1016/j.crohns.2013.10.013. Epub 2013 Nov 21. J Crohns Colitis. 2014. PMID: 24268978
-
Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.J Crohns Colitis. 2011 Apr;5(2):157-61. doi: 10.1016/j.crohns.2010.11.001. Epub 2010 Dec 7. J Crohns Colitis. 2011. PMID: 21453886
-
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.Am J Gastroenterol. 2015 Aug;110(8):1186-96. doi: 10.1038/ajg.2015.205. Epub 2015 Jul 21. Am J Gastroenterol. 2015. PMID: 26195181
-
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. BioDrugs. 2010. PMID: 21175228 Review.
-
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.Rev Gastroenterol Disord. 2004;4 Suppl 3:S25-33. Rev Gastroenterol Disord. 2004. PMID: 15583528 Review.
Cited by
-
Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.Pharmacogenomics J. 2016 Aug;16(4):336-40. doi: 10.1038/tpj.2015.53. Epub 2015 Jul 21. Pharmacogenomics J. 2016. PMID: 26194362
-
Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.J Am Acad Dermatol. 2017 Feb;76(2):334-341. doi: 10.1016/j.jaad.2016.08.012. Epub 2016 Oct 5. J Am Acad Dermatol. 2017. PMID: 27720274 Free PMC article.
-
Paradoxical inflammation induced by anti-TNF agents in patients with IBD.Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):496-503. doi: 10.1038/nrgastro.2012.125. Epub 2012 Jul 3. Nat Rev Gastroenterol Hepatol. 2012. PMID: 22751454 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical